Prizes and Parasites: Incentive Models for Addressing Chagas Disease

Recent advances in immunology have provided a foundation of knowledge to understand many of the intricacies involved in manipulating the human response to fight parasitic infections, and a great deal has been learned from malaria vaccine efforts regarding strategies for developing parasite vaccines. There has been some encouraging progress in the development of a Chagas vaccine in animal models. A prize fund for Chagas could be instrumental in ensuring that these efforts are translated into products that benefit patients.     

Public research and the innovation performance of new technology based firms

Assessing the role of publicly funded scientific research in entrepreneurial ecosystems is of great interest for science and entrepreneurship policy. Knowledge from academic research flows into the private sector through publications, patents, and researcher mobility as well as through direct interactions between founders and researchers at public research institutions (PRIs). New technology-based firms (NTBFs) are generally praised for high innovativeness despite their resource constraints and liability of newness. This study therefore investigates the impact of direct interactions with PRIs on NTBFs’ innovation success. In a large sample of NTBFs in Germany, we find that those firms engaging in such knowledge interactions are more likely to introduce new products and services to the market. The strength of this association, however, depends on interaction persistency, internal R&D and the founders’ academic backgrounds. Non-academic start-ups benefit more from continuous informal interactions if they pursue own R&D, which suggests that absorptive capacity matters. In academic start-ups, higher intensities of both formal and informal interactions are associated with greater innovation likelihood. Moreover, continuous informal interactions complement formal ones in the absence of own R&D activity.

     

Towards a broad understanding of innovation and its importance for innovation policy

This paper considers the changes in the concept of innovation during recent decades and the degree to which such changes have been of significance to innovation policy. We observe that: (1) the notion of innovation in research, statistics, and policy is becoming increasingly broad; (2) while this broader notion is conceptually more adequate for understanding the complexity of innovation activity, it also makes it increasingly difficult to gain a clear, unambiguous picture of innovation activity; (3) policy concepts built upon this extended understanding of innovation are becoming more complex in terms of governance capacities, coordination capabilities, and evidence-based policy formulation. The broad perception of innovation will, in fact, require substantial innovations in political and administrative systems to apply.     

National innovation systems and the globalization of nanotechnology innovation

While there has been much emphasis over the last decade on the science of nanotechnology and on the implications and risks of potential applications, it is now timely to increase attention to the emerging dynamics of nanotechnology commercialization. This paper examines, from a global perspective, where and how corporations are entering into nanotechnology innovation. The paper tests the proposition that a significant shift has occurred in recent years in the orientation of corporate nanotechnology activities—from research discovery to patented applications. It also examines the extent to which the character and structure of corporate nanotechnology activity by country initially reflects national innovation system characteristics and prior public research funding inputs in the stage when discovery is most emphasized. The results indicate that national innovation systems characteristics are significant factors in the commercialization shift of nanotechnology and highlight the importance of innovation system policy factors. We also observe the influence of cross-border international invention linkages, suggesting that national innovation policies also need to be open and international in orientation.     

Thin layer chromatography for the analysis of certain anti-inflammatory medicines

This work was devoted to the elucidation of conditions for isolation of ketorolac and diclofenac from biological fluids. A method is proposed for the extraction of these compounds from solutions with organic solvents at different pH values. Other methods permit to optimize identification of analytes by thin layer chromatography while the densitometric technique may be used for qualitative and quantitative analysis of their composition in biological fluids.     

Establishment of vaccination clinics; user fees for investigational new drug (IND) influenza vaccine services and vaccines. Interim final rule and request for comments

We are amending 42 CFR part 70 to establish vaccination clinics and a user fee in connection with the administration of vaccination services and vaccine. On December 7, 2004, HHS Secretary Tommy G. Thompson announced the purchase of 1.2 million doses of GlaxoSmithKline (GSK) influenza vaccine, Fluarix, for distribution to areas most in need as determined by State public health authorities. The Fluarix vaccine has been approved in seventy-eight foreign countries, and FDA has recently reviewed extensive manufacturing and summary clinical information and conducted an inspection of the GSK manufacturing facility in Germany to determine that this vaccine, although not licensed in the United States, is suitable for use under an Investigational New Drug application (IND). The Food and Drug Administration (FDA) reviewed GSK's IND application as well as the clinical protocol and manufacturing data. CDC and CDC's Institutional Review Board approved the GSK flu vaccine response protocol including the informed consent document. To ensure that the vaccine is properly administered to individuals identified to be most at risk and facilitate compliance with IND requirements, CDC is establishing vaccination clinics. CDC is proceeding without delay because of the unprecedented nature of this season's influenza vaccine shortage caused by contamination problems with Chiron Corporation's production facility in the United Kingdom, which effectively cut in half the expected United States supply of inactivated influenza vaccine. A user fee is being established in order to recoup the costs associated with administering the vaccine and for the vaccine itself. All individuals, other than those who are enrolled in Medicare Part B, will be required to pay the user fee.     

技术创新与制度创新的关系

本文从技术创新与制度创新的概念出发，论述技术创新与制度创新之间的辩证关系。尤其是制度在不适应生产力发展的状况下，即制度不均衡的情况下，对经济发展起重要作用的不是技术，而是制度的创新。     

Priority-setting processes for medicines: the United Kingdom, Australia and New Zealand

The agencies involved in the assessment and prioritisation of medicines for public subsidy purposes in Australia, England and Wales, and New Zealand are compared in terms of their processes; ultimate decision-maker and political involvement in decisions; price-setting processes; decision criteria and inclusion of economic assessment of cost-effectiveness; provision for the rule of rescue and separate treatment of potentially life-saving medicines and cancer drugs; levels of access; extent of consumer participation in processes and decisions; and provision for appeal from decisions. All countries face the key challenge of expanding access to important new treatments, while maintaining cost-effectiveness as a key criterion for public funding and safeguarding the affordability and sustainability of their programs into the future. New Zealand's model may have led to a greater focus on cost-containment and overall affordability than those of the other two agencies. Despite controversial decisions that have led on occasion to disappointment and challenge, the Australian and New Zealand agencies have survived and appear to have managed to date to maintain public and political support. By contrast, the United Kingdom's National Institute for Healthcare and Clinical Excellence is facing major changes to its role that could see it become more of an advisory organisation.     

Profiling of counterfeit medicines by vibrational spectroscopy

Counterfeit pharmaceutical products have become a widespread problem in the last decade. Various analytical techniques have been applied to discriminate between genuine and counterfeit products. Among these, Near-infrared (NIR) and Raman spectroscopy provided promising results. The present study offers a methodology allowing to provide more valuable information for organisations engaged in the fight against counterfeiting of medicines. A database was established by analyzing counterfeits of a particular pharmaceutical product using Near-infrared (NIR) and Raman spectroscopy. Unsupervised chemometric techniques (i.e. principal component analysis - PCA and hierarchical cluster analysis - HCA) were implemented to identify the classes within the datasets. Gas Chromatography coupled to Mass Spectrometry (GC-MS) and Fourier Transform Infrared Spectroscopy (FT-IR) were used to determine the number of different chemical profiles within the counterfeits. A comparison with the classes established by NIR and Raman spectroscopy allowed to evaluate the discriminating power provided by these techniques. Supervised classifiers (i.e. k-Nearest Neighbors, Partial Least Squares Discriminant Analysis, Probabilistic Neural Networks and Counterpropagation Artificial Neural Networks) were applied on the acquired NIR and Raman spectra and the results were compared to the ones provided by the unsupervised classifiers. The retained strategy for routine applications, founded on the classes identified by NIR and Raman spectroscopy, uses a classification algorithm based on distance measures and Receiver Operating Characteristics (ROC) curves. The model is able to compare the spectrum of a new counterfeit with that of previously analyzed products and to determine if a new specimen belongs to one of the existing classes, consequently allowing to establish a link with other counterfeits of the database.     

Drivers for international innovation activities in developed and emerging countries

This paper aims to shed light on firm-specific drivers that lead firms to internationalise their innovation activities. The paper paints a comprehensive picture of driving forces by including firm capabilities, characteristics of the firm’s competitive environment and the influence of innovation obstacles in the home country. In particular the influence of potential driving forces on the probability to carry out different innovative activities abroad is assessed (R&D, design/conception of new products, manufacturing of innovative products and implementation of new processes). In a second stage these driving forces are observed with regard to their impact on the decision to locate innovation activities in various countries and regions (China, Eastern Europe, Western Europe and North America) as well as in groups of countries with similar levels of knowledge (“country clubs”). The analysis is based on the Mannheim Innovation Panel survey which represents the German CIS (Community Innovation Survey) contribution. Two survey waves have been combined, resulting in a sample of about 1,400 firms. The results show that the decision to perform innovation activities abroad is mainly driven by organisational capabilities such as absorptive capacities, international experience and existing technological competences of the respective firm. Innovation barriers at the German home base such as lack of labour and high innovation costs prompt the set-up of later-stage innovation activities abroad while the lack of demand demonstrates a barrier to the internationalisation decision for the development and manufacturing of new products. Location decisions receive the strongest influencing effects from the international experience of the firm. Firms which innovate in developing countries seem to require a more extensive level of international experience through international R&D cooperation.     

Dimensions of innovation

Within a conceptual framework of three dimensions, this paper examines parallels between the process of innovation in ship-building and in nursing care. Major conclusions are:

1. A given innovation must include not only technological change but also embedding activities to ensure its fit into the adopting organization.
2. To ensure continuation of the innovating process, it is necessary to build innovative capacity, with leadership vested in some person or group.
3. System-wide innovation requires both an effective diffusion process and diffusion capacity, to disseminate knowledge about specific innovations and also about ways to build innovative capacity.
4. Building both innovative capacity and diffusion capacity must be seen as responsibilities of the entire organization or system.

     

Canada/US: bioterrorism highlights double standard for access to medicines

In September 2001, shortly after terrorist attacks in the United States, the issue of bioterrorism--and specifically fear about reported cases of anthrax in the US--led the Canadian Minister of Health to be concerned about the available stocks of the drug ciprofloxacin to treat this disease.     

The role of proximity in university-business cooperation for innovation

The potential for universities to contribute positively to business innovation has received much attention in recent years. While the determinants of university-business cooperation have been examined extensively, less attention has been given to the mediating influence of proximity in this relationship. The analysis in this paper builds on the UK business innovation survey (2002–2005) by incorporating measures of the university research environment for each of the 16,500 businesses surveyed. These measures allow us to look beyond business-level characteristics as determinants of the geography of university cooperation and account for the character of the local university environment. Measures include the distance from each business to its nearest university, the quality of local university research and the density of the university research environment. The findings suggest that significant differences exist between those businesses that cooperate with local universities and those that cooperate with non-local universities. These differences relate to business size, sales profile, location, absorptive capacity and innovation activity. In addition, we also find that if a business is located close to a research excellent university, cooperation tends to remain local, however, the distance between businesses and the nearest university is not a significant determinant of university-business cooperation and further, the higher the concentration of universities in the business locale, the more likely businesses are to cooperate with non-local universities.     

University-industry collaborations and product innovation performance: the moderating effects of absorptive capacity and innovation competencies

While the performance implications of university-industry collaboration (UIC) have been the subject of extensive research, no study thus far has investigated the potential influence of absorptive capacity and innovation competencies on the relationship between UIC and product innovation performance. Based on a sample of 2061 German companies from two waves of the German Community Innovation Survey and using moderated multiple regression, this study examines these moderating effects and provides the following findings: (1) absorptive capacity in terms of internal R&D negatively moderates the relationship between UIC and incremental innovation performance and has no effect on the relationship between UIC and radical innovation performance; (2) absorptive capacity related to employee know-how has no moderating effect on the relationship between UIC and incremental innovation performance but positively moderates the relationship between UIC and radical innovation performance; and (3) innovation competencies exert no moderating effect on the relationship between UIC and incremental innovation performance but have a predominantly positive moderating effect on the relationship between UIC and radical innovation performance. In summary, our study provides relevant insights on the dynamics governing UIC relationships and provides evidence for potential negative effects of absorptive capacity in the context of collaborative R&D (substitution effect). Providing an in-depth analysis of UIC, this study offers insights for research in this field by explaining the variance in the outcomes of UIC. Moreover, our findings have the potential to aid practitioners (e.g., innovation managers, researchers, and governing and funding bodies) in their decisions concerning their involvement in UIC.     

An innovation economics agenda for the Obama administration

Seven recommendations are offered for the Obama Administration to ensure that the economy is on a robust growth path over the next decade. These recommendations are intended as first steps towards building the innovation-based public-private partnerships needed to drive economic growth and prosperity.